-
Intercept Pharmaceuticals NASDAQ:ICPT Acquired by Alfasigma S.p.A. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
Location: | Website: www.interceptpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
126.6M
Avg Qtr Burn
N/A
Short % of Float
27.80%
Insider Ownership
3.13%
Institutional Own.
81.30%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OCALIVA® (obeticholic acid) Details Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease | Approved Quarterly sales | |
Ocaliva + Bezafibrate Details Primary biliary cholangitis, Liver disease | Phase 2 Update | |
INT-787 Details Liver disease, Alcoholic hepatitis | Phase 2a Update | |
Ocaliva Details Primary sclerosing cholangitis, Liver disease | Failed Discontinued | |
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued | |
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued |